A Novel Antigen Design Strategy to Isolate Single‐Domain Antibodies that Target Human Nav1.7 and Reduce Pain in Animal Models
Advanced Science · 2024
DOI: 10.1002/advs.202405432 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Marzia Martina und 20 weiteren Autor:innen. Beteiligte Einrichtung: Human Health Therapeutics Research Center, National Research Council Canada, 1200 Montreal Road, Building M54, Ottawa, ON, K1A 0R6, Canada. Hauptthemen laut MEDLINE: Antigens, Single-Domain Antibodies, NAV1.7 Voltage-Gated Sodium Channel, Pain. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Genetic studies have identified the voltage‐gated sodium channel 1.7 ( Na v 1.7 ) as pain target. Due to the ineffectiveness of small molecules and monoclonal antibodies as therapeutics for pain, single‐domain antibodies ( V H Hs ) are developed against the human Na v 1.7 ( hNa v 1.7 ) using a novel antigen presentation strategy. A 70 amino‐acid peptide from the hNa v 1.7 protein is identified as a target antigen. A recombinant version of this peptide is grafted into the complementarity determining region 3 ( CDR3 ) loop of an inert V H H in order to maintain the native 3D conformation of the peptide. This antigen is used to isolate one V H H able to i) bind hNa v 1.7, ii) slow the deactivation of hNa v 1.7, iii) reduce the ability of eliciting action potentials in nociceptors, and iv) reverse hyperalgesia in in vivo rat and mouse models. This V H H exhibits the potential to be developed as a therapeutic capable of suppressing pain. This novel antigen presentation strategy can be applied to develop biologics against other difficult targets such as ion channels, transporters and GPCRs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Human Health Therapeutics Research Center, National Research Council Canada, 1200 Montreal Road, Building M54, Ottawa, ON, K1A 0R6, Canada.
- Human Health Therapeutics Research Centre, National Research Council Canada, 100 Sussex Drive, Ottawa, ON, K1N 5A2, Canada.
- Human Health Therapeutics Research Centre, National Research Council Canada, 6100 Royalmount Avenue Montréal, Quebec, H4P 2R2, Canada.
ORCID-Profile: Marzia Martina, Umberto Banderali, Mehdi Arbabi Ghahroudi, Traian Sulea, Yves Durocher, Greg Hussack, Henk van Faassen, Umar Iqbal, Binbing Ling, Etienne Lessard, Joey Sheff, Anna Robotham, Tanya Comas, Danica Stanimirovic
Zitieren
APA
Martina, M., Banderali, U., Yogi, A., Arbabi Ghahroudi, M., Liu, H., Sulea, T., Durocher, Y., Hussack, G., van Faassen, H., Chakravarty, B., Liu, Q. Y., Iqbal, U., Ling, B., Lessard, E., Sheff, J., Robotham, A., Callaghan, D., Moreno, M., Comas, T., …, & Stanimirovic, D. (2024). A Novel Antigen Design Strategy to Isolate Single‐Domain Antibodies that Target Human Nav1.7 and Reduce Pain in Animal Models. Advanced Science. https://doi.org/10.1002/advs.202405432
Vancouver
Martina M, Banderali U, Yogi A, Arbabi Ghahroudi M, Liu H, Sulea T, et al. A Novel Antigen Design Strategy to Isolate Single‐Domain Antibodies that Target Human Nav1.7 and Reduce Pain in Animal Models. Advanced Science. 2024. doi:10.1002/advs.202405432
BibTeX
@article{Martina2024,
author = {Martina, Marzia and Banderali, Umberto and Yogi, Alvaro and Arbabi Ghahroudi, Mehdi and Liu, Hong and Sulea, Traian and Durocher, Yves and Hussack, Greg and van Faassen, Henk and Chakravarty, Balu and Liu, Qing Yan and Iqbal, Umar and Ling, Binbing and Lessard, Etienne and Sheff, Joey and Robotham, Anna and Callaghan, Debbie and Moreno, Maria and Comas, Tanya and Ly, Dao and Stanimirovic, Danica},
title = {A Novel Antigen Design Strategy to Isolate Single‐Domain Antibodies that Target Human Nav1.7 and Reduce Pain in Animal Models},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202405432}
}
EUVIMED